Product
Datopotamab deruxtecan
Aliases
Dato-DXd, DS-1062a
Name
Dato-DXd
Target
TROP2
FDA Approved
No
Ema approved
Status
0
9 clinical trials
2 abstracts
19 indications
Indication
NSCLCIndication
Breast NeoplasmsIndication
Breast Cancer Stage IVIndication
Breast CancerIndication
Breast TumorsIndication
AngiosarcomaIndication
Triple-Negative Breast CancerIndication
Breast Cancer (HER2-positive)Indication
Hormone Receptor Positive TumorIndication
Hormone Receptor Negative TumorIndication
Locally Advanced Breast CancerIndication
Endometrial CancerIndication
Stomach CancerIndication
Ovarian CancerIndication
Colorectal CancerIndication
Bladder CancerIndication
Bile Duct CancerIndication
Metastatic Non Small Cell Lung CancerClinical trial
Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)Status: Recruiting, Estimated PCD: 2027-02-22
Clinical trial
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)Status: Recruiting, Estimated PCD: 2026-01-30
Clinical trial
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.Status: Active (not recruiting), Estimated PCD: 2025-05-06
Abstract
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cheng Kung University, Daiichi Sankyo Inc., Taichung Veterans General Hospital, Mayo Clinic,
Clinical trial
A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-11-14
Clinical trial
Phase II Study of Datopotamab-Deruxtecan (Dato-DXd; DS-1026a) in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain MetastasesStatus: Recruiting, Estimated PCD: 2026-05-23
Clinical trial
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)Status: Recruiting, Estimated PCD: 2030-12-01
Clinical trial
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid TumoursStatus: Recruiting, Estimated PCD: 2026-08-19